First Trust创新领袖主动型ETF ILDR 深 沪
等待开盘 07-03 09:30:00 美东时间
38.239
-0.691
-1.77%
华盛通- 最 高39.27
- 今 开38.66
- 成交量 3.15万股
- 最 低 37.995
- 昨 收 38.93
- 总市值 2.87亿
- 52周最高 40.84
- 市盈率 静 --
- 换手率 0.42%
- 52周最低 28.1901
- 委 比 0.00%
- 总股本 750.00万
- 历史最高 40.84
- 量 比 0.42
- 振 幅 3.28%
- 历史最低 13.109
- 每 手 1
- 风险率 2.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UPDATE 1-Australia gives regulator more power to pursue Big Tech over under-16 ban
UPDATE 1-Australia gives regulator more power to pursue Big Tech over under-16 ban Government introduces bill to toughen social media ban to parliament eSafety Commissioner to be given more information-gathering powers Australia is investigating five platforms for non-compliance Adds comments from W
06-29 16:09
BRIEF-U.S. FDA Approves Pfizer’S Hympavzi For The Treatment Of Two Additional Hemophilia A Or B Patient Populations With Significant Medical Need
BRIEF-U.S. FDA Approves Pfizer’S Hympavzi For The Treatment Of Two Additional Hemophilia A Or B Patient Populations With Significant Medical Need June 8 (Reuters) - Pfizer Inc PFE.N : U.S. FDA APPROVES PFIZER’S HYMPAVZI FOR THE TREATMENT OF TWO ADDITIONAL HEMOPHILIA A OR B PATIENT POPULATIONS WITH S
06-08 18:46
BRIEF-Australia's ACCC Says Amazon In Court Over Alleged Missing Button Battery Warnings On Children's Unicorn Backpacks
BRIEF-Australia's ACCC Says Amazon In Court Over Alleged Missing Button Battery Warnings On Children's Unicorn Backpacks May 29 (Reuters) - Australia's ACCC: AMAZON IN COURT OVER ALLEGED MISSING BUTTON BATTERY WARNINGS ON CHILDREN'S UNICORN BACKPACKS AMAZON AU HAD POSSESSION OR CONTROL OF BACKPACKS
05-29 09:11
BRIEF-Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program After Strong Positive Phase 2 Results
BRIEF-Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program After Strong Positive Phase 2 Results May 20 (Reuters) - Pfizer Inc PFE.N : PFIZER: ADVANCES PIVOTAL PEDIATRIC PNEUMOCOCCAL VACCINE PROGRAM FOLLOWING STRONG POSITIVE PHASE 2 RESULTS PFIZER: 25VPNC PHASE 2 DATA SHOWS ROBUST IMMUNOGE
05-20 17:05
BRIEF-Lilly And Unicef Collaborate To Give Millions Of Children A Healthier Start
BRIEF-Lilly And Unicef Collaborate To Give Millions Of Children A Healthier Start Eli Lilly and Co LLY.N : LILLY AND UNICEF COLLABORATE TO GIVE MILLIONS OF CHILDREN A HEALTHIER START ELI LILLY - COMMITS $50 MILLION TO UNICEF TO STRENGTHEN PRIMARY HEALTHCARE FOR NCDS Source text: ID:nPn5WDMXFa Furthe
05-14 19:00
BRIEF-Nexstim Receives Order From Children Hospital In U.S.
BRIEF-Nexstim Receives Order From Children Hospital In U.S. May 5 (Reuters) - Nexstim Oyj NXTMH.HE : NEXSTIM RECEIVES NBS 6 SYSTEM ORDER FROM CHILDREN’S HOSPITAL IN THE U.S. Source text: https://mfn.se/ind/a/nexstim/nexstim-receives-nbs-6-system-order-from-childrens-hospital-in-the-u-s-7bb1300f Furt
05-05 14:08
BRIEF-Sanofi's Tzield Approved In US To Delay Onset Of Stage 3 Type 1 Diabetes In Young Children
BRIEF-Sanofi's Tzield Approved In US To Delay Onset Of Stage 3 Type 1 Diabetes In Young Children April 22 (Reuters) - Sanofi SA SASY.PA : REG-PRESS RELEASE: SANOFI'S TZIELD APPROVED IN THE US TO DELAY THE ONSET OF STAGE 3 TYPE 1 DIABETES IN YOUNG CHILDREN FDA APPROVES TZIELD TO DELAY STAGE 3 TYPE 1
04-22 13:28
BRIEF-Sun Pharma Announces Us FDA Acceptance Of Supplemental Biologics License (Sbla) Application For Ilumya® (Tildrakizumab-Asmn) For The Treatment Of Adults With Active Psoriatic Arthritis
BRIEF-Sun Pharma Announces Us FDA Acceptance Of Supplemental Biologics License (Sbla) Application For Ilumya® (Tildrakizumab-Asmn) For The Treatment Of Adults With Active Psoriatic Arthritis March 16 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS : SUN PHARMA ANNOUNCES US FDA ACCEPTANCE OF SUP
03-16 19:34
BRIEF-The Children’S Place Announces Senior Leadership Appointments
BRIEF-The Children’S Place Announces Senior Leadership Appointments Children's Place Inc PLCE.O : THE CHILDREN’S PLACE ANNOUNCES SENIOR LEADERSHIP APPOINTMENTS Source text: ID:nGNXkMb2t Further company coverage: PLCE.O
02-24 22:18
BRIEF-Takeda's ENTYVIO Shows Promise For Treating Ulcerative Colitis In Children
BRIEF-Takeda's ENTYVIO Shows Promise For Treating Ulcerative Colitis In Children Feb 19 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T : POSITIVE PHASE 3 DATA DEMONSTRATE POTENTIAL FOR ENTYVIO® (VEDOLIZUMAB) TO ADDRESS TREATMENT GAP FOR CHILDREN AND ADOLESCENTS WITH MODERATE TO SEVERE ULCERATIVE CO
02-20 01:40
